DE68917186D1 - Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie. - Google Patents

Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie.

Info

Publication number
DE68917186D1
DE68917186D1 DE68917186T DE68917186T DE68917186D1 DE 68917186 D1 DE68917186 D1 DE 68917186D1 DE 68917186 T DE68917186 T DE 68917186T DE 68917186 T DE68917186 T DE 68917186T DE 68917186 D1 DE68917186 D1 DE 68917186D1
Authority
DE
Germany
Prior art keywords
ofloxacin
otopathy
salts
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68917186T
Other languages
English (en)
Other versions
DE68917186T2 (de
Inventor
Kiichi Sato
Akira C O Daiichi Seiyak Handa
Takeji C O Daiichi Se Kitahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13885215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68917186(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of DE68917186D1 publication Critical patent/DE68917186D1/de
Application granted granted Critical
Publication of DE68917186T2 publication Critical patent/DE68917186T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DE68917186T 1988-04-08 1989-04-07 Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie. Expired - Lifetime DE68917186T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63086378A JPH01258620A (ja) 1988-04-08 1988-04-08 耳疾患用局所製剤

Publications (2)

Publication Number Publication Date
DE68917186D1 true DE68917186D1 (de) 1994-09-08
DE68917186T2 DE68917186T2 (de) 1995-01-05

Family

ID=13885215

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68917186T Expired - Lifetime DE68917186T2 (de) 1988-04-08 1989-04-07 Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie.

Country Status (16)

Country Link
US (1) US5401741A (de)
EP (1) EP0337328B1 (de)
JP (2) JPH01258620A (de)
KR (1) KR0126471B1 (de)
AT (1) ATE109350T1 (de)
AU (1) AU614349B2 (de)
CA (1) CA1330946C (de)
DE (1) DE68917186T2 (de)
DK (1) DK175302B1 (de)
HK (1) HK196596A (de)
HU (1) HU00407A9 (de)
IE (1) IE65859B1 (de)
IL (1) IL89807A (de)
NZ (1) NZ228632A (de)
PH (1) PH26367A (de)
ZA (1) ZA892449B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686095A (en) * 1995-10-23 1997-11-11 Price, Jr.; Francis W. Method of treating canker sores
US5753269A (en) * 1995-12-27 1998-05-19 Bayer Corporation Otic microbial combinations
US5997893A (en) * 1998-01-20 1999-12-07 Ethicon, Inc. Alcohol based anti-microbial compositions with cosmetic appearance
US5972358A (en) * 1998-01-20 1999-10-26 Ethicon, Inc. Low tack lotion, gels and creams
US6248343B1 (en) 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
US6022551A (en) * 1998-01-20 2000-02-08 Ethicon, Inc. Antimicrobial composition
US5912255A (en) * 1998-02-27 1999-06-15 Bussell; Letantia Topical fluoroquinolone antibiotics combined with benzoyl peroxide
US6017912A (en) * 1998-02-27 2000-01-25 Bussell; Letantia Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle
EP1025846B1 (de) * 1998-08-21 2006-07-12 Senju Pharmaceutical Co., Ltd. Wässerige flüssige zubereitungen
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
MXPA03002342A (es) * 2000-09-25 2004-10-15 Bayer Healthcare Llc Combinaciones microbianas opticas para el tratamiento de animales con la membrana timpanica rota.
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8030362B2 (en) * 2003-12-12 2011-10-04 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
KR20160047490A (ko) 2013-08-27 2016-05-02 오토노미, 인코포레이티드 소아 귀 질환의 치료
EP3512513A4 (de) 2016-09-16 2020-04-15 Otonomy, Inc. Gelformulierungen für das ohr zur behandlung von otitis externa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260416A (en) * 1979-09-04 1981-04-07 Allied Chemical Corporation Amorphous metal alloy for structural reinforcement
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
JPS638333A (ja) * 1986-06-30 1988-01-14 Dai Ichi Seiyaku Co Ltd 外用剤
JP2558107B2 (ja) * 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
CA1309024C (en) * 1986-12-19 1992-10-20 Hiromitsu Seki Aqueous pharmaceutical composition containing s-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl -7-oxo-2,3,-dihydro-7h-pyridol[1,2,3,-de][1,4]benzoxazine -6-carboxylic acid

Also Published As

Publication number Publication date
IL89807A (en) 1993-08-18
DK168189D0 (da) 1989-04-07
EP0337328A3 (de) 1991-12-27
EP0337328A2 (de) 1989-10-18
JP2573351B2 (ja) 1997-01-22
AU614349B2 (en) 1991-08-29
IE65859B1 (en) 1995-11-29
ATE109350T1 (de) 1994-08-15
EP0337328B1 (de) 1994-08-03
HK196596A (en) 1996-11-01
DE68917186T2 (de) 1995-01-05
ZA892449B (en) 1989-12-27
HU00407A9 (en) 1995-09-28
KR0126471B1 (ko) 1997-12-24
JPH0334925A (ja) 1991-02-14
US5401741A (en) 1995-03-28
NZ228632A (en) 1991-10-25
AU3256789A (en) 1989-10-12
KR890015742A (ko) 1989-11-25
JPH01258620A (ja) 1989-10-16
DK168189A (da) 1989-10-09
PH26367A (en) 1992-06-01
DK175302B1 (da) 2004-08-16
CA1330946C (en) 1994-07-26
IE891118L (en) 1989-10-08

Similar Documents

Publication Publication Date Title
DE68917186T2 (de) Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie.
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES2031913T3 (es) Un procedimiento para preparar un derivado de quinazolinona.
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
ATE145136T1 (de) Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE83378T1 (de) Verwendung von 3'-azido-deoxythymidin zur herstellung eines arzneimittels zur behandlung von humanen brustcarzinomen.
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
DE3766619D1 (de) Verwendung von dicarbonsaeuren mit 7-13 kohlenstoffatomen oder physiologisch vertraeglichen salzen davon zur herstellung eines arzneimittels zur topischen behandlung von rosazea.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
ATA149580A (de) Verfahren zur herstellung neuer, zur behandlung von psoriasis dienender 1,8-dihydroxy-10-acyl-9 -anthrone
AT378958B (de) Verfahren zur herstellung von neuen derivaten des 1,4-chinolyl-2-(4-piperidyl)-aethanols oder des 1,4-chinolyl-3-(4-piperidyl)-propanols und deren salzen
ATA917478A (de) Herstellung des neuen n-(5-methoxybenzofuran-2-yl-carbonyl)n'-benzylp perazins oder dessen saeure- additionssalzen
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE69116216D1 (de) Verwendung von Squalene, Squalane oder deren Mischungen zur Herstellung einer abkühlenden Zusammensetzung zur örtlichen Behandlung von Verbrennungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE68906700D1 (de) Verwendung eines polypeptids zur herstellung einer zusammensetzung zur behandlung von pankreatitis.
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
DE69529070D1 (de) Verwendung von 5,6-o-benzyliden-l-ascorbinsäure oder deren salze zur herstellung eines medikaments zur behandlung von hiv
DE3584426D1 (de) Verwendung von spergualin oder eines seiner pharmazeutisch akzeptablen salze zur herstellung eines transplantation-immunitaet unterdrueckenden und anti-allergischen mittels.
ATE58831T1 (de) Verwendung von dicarbonsaeuren mit 7-13 kohlenstoffatomen oder physiologisch vertraeglichen salzen davon zur herstellung eines arzneimittels zur topischen behandlung von rosazea.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI SANKYO CO., LTD., TOKYO, JP